Hemispherx Biopharmas Ampligen treatment aims to disrupt the cancer market

Hemispherx Biopharma’s Ampligen treatment aims to disrupt the cancer market

08:36 EDT 5 Jul 2019 | Proactive Investors

CEO Tom Equels says Ampligen on a standalone basis has demonstrated effects in 'a number of solid tumors'

More From BioPortfolio on "Hemispherx Biopharma’s Ampligen treatment aims to disrupt the cancer market"